No business profile yet.
Size Mani (7730.T) is a Japan Health Care company (Medical Specialties) with a market value of $965M, the 756th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,552 on 18 Nov 2026.
Performance Over six months the shares fell 6.8%, against -11.7% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 10.2% over the last twelve months (peer median +10.4%); the operating margin is 30.1% (peer median 9.6%).
Valuation It trades at 19.9× forward earnings against a peer median of 20.9× (8th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.0 points above its cost of capital (8.2% WACC).
Next results Next results expected around 13 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | ¥33.0B | ¥33.0B | ¥30.0B | ¥28.5B | ¥24.5B |
| Revenue growth | — | +10% | +5% | +16% | — |
| Gross profit | ¥22.0B | ¥22.0B | ¥18.9B | ¥17.5B | ¥15.1B |
| EBITDA | ¥12.4B | ¥12.4B | ¥10.7B | ¥10.7B | ¥9.16B |
| Net income | ¥7.24B | ¥7.24B | ¥4.64B | ¥6.29B | ¥5.95B |
| Free cash flow | n/a | ¥10.7B | ¥612M | ¥397M | ¥4.52B |
| Capital expenditure | n/a | ¥1.15B | ¥6.67B | ¥7.68B | ¥3.72B |
| Total debt | ¥81.0M | ¥81.0M | ¥76.0M | ¥83.0M | ¥58.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7730.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.2% | -6.0% | 7th highest of 21 |
| 6-month return | -6.8% | -11.7% | 8th highest of 21 |
| Distance from 52-week high | -20.6% | -30.5% | 5th highest of 21 |
| Revenue growth (TTM) | +10.2% | +10.4% | 11th highest of 21 |
| Operating margin | 30.1% | 9.6% | 3rd highest of 21 |
| Forward P/E | 19.9× | 20.9× | 8th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 3.3% | 7.6% | 5th least demanding of 15 |
| Growth delivered (Del g) | +13.9% | +12.1% | 5th highest of 15 |
| Hurdle (Req g minus delivered) | -10.7 pp | -3.7 pp | 2nd least demanding of 15 |
| ROIC minus cost of capital | +13.0 pp | +2.8 pp | 6th highest of 20 |
| EV / EBITDA | 10.3× | 10.4× | 6th cheapest of 11 |
| Net debt / EBITDA | -2.1× | 0.3× | least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 19.9× | 3.3% | +13.9% |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 18.7× | -6.1% | +11.7% |
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 15.8× | 1.3% | +4.7% |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 50.3× | 10.7% | +12.9% |
| Menicon 7780.T | Japan | $944M | +26% | +6% | 9% | 20.9× | n/a | n/a |
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | n/a | 32.6% | +21.0% |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | n/a | n/a | n/a |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 18.0× | 6.9% | -2.9% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% | +10.4% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $907M | -12% | +41% | 6% | 70.5× | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | n/a | 57.7% | +40.6% |
| Artivion AORT | United States | $905M | -18% | +14% | 5% | 383.6× | n/a | n/a |
| Bioventus BVS | United States | $895M | -3% | +4% | 10% | 13.0× | 7.5% | +12.1% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $888M | -12% | +17% | 18% | 26.2× | 19.3% | +23.3% |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |
| Shenzhen YHLO Biotech 688575.SS | China | $882M | -16% | +3% | 12% | 30.7× | 2.0% | +12.7% |
| Hangzhou Biotest Biotech 688767.SS | China | $878M | -12% | -4% | 3% | 37.0× | n/a | n/a |